Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.69 |
| ▸ | RAB9A | P51151 | 12/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.69 |
| ▸ | TP53 | P04637 | 3/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 13/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 13/20 | 0.67 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 9/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | VCP | P55072 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.56 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18029498 | 0.82 | RAB9A (1.00) | NPC1RAB9ASMN1; SMN2TP53TDP1 | |
| SCHEMBL2703762 | 0.80 | MEN1 (1.00) | NPC1RAB9ASMN1; SMN2TP53TDP1 | |
| SCHEMBL2705358 | 0.80 | MEN1 (0.61) | NPC1RAB9ASMN1; SMN2TP53TDP1 | |
| SCHEMBL2762873 | 0.79 | KDM1A (0.72) | NPC1RAB9ASMN1; SMN2TP53TDP1 | |
| SCHEMBL12639823 | 0.78 | MAPK1 (0.86) | NPC1RAB9ASMN1; SMN2TP53TDP1 | |
| SCHEMBL22680214 | 0.77 | SMN1; SMN2 (0.71) | NPC1RAB9ASMN1; SMN2TDP1MEN1 | |
| SCHEMBL712318 | 0.77 | MEN1 (0.63) | NPC1RAB9ATDP1MEN1KMT2A | |
| SCHEMBL206486 | 0.75 | MEN1 (0.76) | NPC1RAB9ASMN1; SMN2TP53TDP1 | |
| SCHEMBL18083891 | 0.75 | MEN1 (1.00) | NPC1RAB9ASMN1; SMN2TP53TDP1 | |
| SCHEMBL12297431 | 0.75 | MEN1 (0.76) | NPC1RAB9ASMN1; SMN2TP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | PIGS, CPT1A, SLC10A1 | NPC1 62/4885RAB9A 1357/4885SMN1; SMN2 3252/4885 |
| US-20070004711-A1 | Thiazole compounds and methods of use | PIGS, CPT1A, SLC10A1 | NPC1 62/4885RAB9A 1357/4885SMN1; SMN2 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.